

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Australian Pharmaceutical Industries Limited
ABN	57 000 004 320

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Craig Vincent
Date of last notice	8 February 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	29 March 2022

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p>481,833 ordinary shares</p> <p>495,711 performance rights granted under API's Long Term Incentive Plan with a performance period of 1 September 2019 to 31 August 2022</p> <p>825,400 performance rights granted under API's Long Term Incentive Plan with a performance period of 1 September 2020 to 31 August 2023</p> <p>160,900 performance rights granted under API's Short Term Incentive Plan</p> <p>731,730 performance rights granted under API's Long Term Incentive Plan with a performance period of 1 September 2021 to 31 August 2024</p>
Class	Performance Rights
Number acquired	Nil
Number disposed	<p>495,711 performance rights granted under API's Long Term Incentive Plan with a performance period of 1 September 2019 to 31 August 2022 (cancelled)</p> <p>825,400 performance rights granted under API's Long Term Incentive Plan with a performance period of 1 September 2020 to 31 August 2023 (cancelled)</p> <p>160,900 performance rights granted under API's Short Term Incentive Plan (cancelled)</p> <p>731,730 performance rights granted under API's Long Term Incentive Plan with a performance period of 1 September 2021 to 31 August 2024 (cancelled)</p>
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$3,431,298.55
No. of securities held after change	481,833 ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	The cancellation of performance rights previously granted under API's Long Term Incentive Plan and API's Short Term Incentive Plan occurred in connection with the acquisition by WFM Investments Pty Ltd of 100% of the shares in API that it does not already own, by way of a scheme of arrangement under Part 5.1 of the Corporations Act which became effective on 22 March 2022. See Section 9.2 of the Scheme Booklet for more information about the cancellation of these performance rights.
---	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
---	----

⁺ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

+ See chapter 19 for defined terms.